Wall Street analyst estimates for BridgeBio Pharma, Inc. (BBIO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 24 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 27 |
| Avg rating (1-5) | 0.89 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-28 | $-0.61 | ||
| 2026-08-10 | $-0.78 | $-0.58 | -35.5% |
| 2026-05-07 | $-0.84 | $-0.68 | -23.8% |
| 2026-02-24 | $-1.00 | $-0.71 | -40.2% |
| 2025-10-29 | $-0.95 | $-0.88 | -8.0% |
| 2025-08-05 | $-0.95 | $-0.83 | -14.5% |
| 2025-04-29 | $-0.88 | $-1.00 | +12.0% |
| 2025-02-20 | $-1.31 | $-1.09 | -20.2% |
Valuation Ratios
| Price / Book | -5.23 |
| EV / EBITDA | -24.50 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| Cost of Revenue | $260,000 | 0 | $2.5M | 0 | $3.1M | $3.4M | $2.4M | $3.9M | $28.3M |
| Gross Profit | -$260,000 | 0 | $38.1M | $8.2M | $66.6M | $74.2M | $6.9M | $218.0M | $473.8M |
| Research & Development | $30.6M | $140.1M | $209.9M | $337.0M | $451.0M | $399.5M | $455.7M | $506.5M | $477.5M |
| Selling, General & Admin | $13.3M | $43.6M | $94.4M | $145.7M | $192.2M | $143.2M | $150.6M | $288.9M | $555.1M |
| Operating Expenses | $43.9M | $183.7M | $304.3M | $482.7M | $643.2M | $586.4M | $614.2M | $811.0M | $1.04B |
| Operating Income | -$43.9M | -$183.7M | -$266.2M | -$474.5M | -$576.6M | -$512.2M | -$607.4M | -$593.0M | -$569.1M |
| EBITDA | -$43.6M | -$183.4M | -$279.0M | -$467.4M | -$533.8M | -$397.4M | -$565.5M | -$436.8M | -$672.9M |
| Interest Expense | $13,000 | $2.5M | $8.8M | $36.7M | $46.8M | $80.4M | $81.3M | $99.3M | $53.1M |
| Pre-tax Income | -$43.8M | -$169.5M | -$288.6M | -$505.5M | -$586.5M | -$484.7M | -$653.3M | -$542.2M | -$735.0M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.2M | $555,000 |
| Net Income | -$30.6M | -$130.7M | -$260.4M | -$448.7M | -$562.5M | -$481.2M | -$643.2M | -$535.8M | -$729.3M |
| EPS | $-0.33 | $-1.42 | $-2.48 | $-4.10 | $-3.90 | $-3.35 | $-3.95 | $-2.88 | $-3.79 |
| EPS (Diluted) | $-0.33 | $-1.42 | $-2.48 | $-4.10 | $-3.90 | $-3.35 | $-3.95 | $-2.88 | $-3.79 |
| Shares Outstanding (Diluted) | $92.3M | $92.3M | $105.1M | $118.0M | $144.4M | $147.5M | $162.8M | $186.1M | $197.2M |
Price
| Price | $66.14 |
| Market Cap | $13.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ASND · BMRN · EXEL · IONS · JAZZ · MRNA · RNA
Explore sector: Healthcare · Biotechnology
More sections of BBIO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks